Article info

Protocol
Efficacy of neoadjuvant atezolizumab treatment in patients with advanced urothelial bladder cancer according to the BASQ classification: a study protocol for an open-label, two-cohort, phase II trial

Authors

  • Hyeong Dong Yuk Urology, Seoul National University Hospital, Seoul, The Republic of KoreaCollege of Medicine, Seoul National University, Seoul, The Republic of Korea PubMed articlesGoogle scholar articles
  • Chang Wook Jeong Urology, Seoul National University Hospital, Seoul, The Republic of KoreaCollege of Medicine, Seoul National University, Seoul, The Republic of Korea PubMed articlesGoogle scholar articles
  • Cheol Kwak Urology, Seoul National University Hospital, Seoul, The Republic of KoreaCollege of Medicine, Seoul National University, Seoul, The Republic of Korea PubMed articlesGoogle scholar articles
  • Hyeon Kim Urology, Seoul National University Hospital, Seoul, The Republic of KoreaCollege of Medicine, Seoul National University, Seoul, The Republic of Korea PubMed articlesGoogle scholar articles
  • Kyung Chul Moon College of Medicine, Seoul National University, Seoul, The Republic of KoreaPathology, Seoul National University Hospital, Seoul, The Republic of Korea PubMed articlesGoogle scholar articles
  • Ja Hyeon Ku Urology, Seoul National University Hospital, Seoul, The Republic of KoreaCollege of Medicine, Seoul National University, Seoul, The Republic of Korea PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Ja Hyeon Ku; kuuro70{at}snu.ac.kr
View Full Text

Citation

Yuk HD, Jeong CW, Kwak C, et al
Efficacy of neoadjuvant atezolizumab treatment in patients with advanced urothelial bladder cancer according to the BASQ classification: a study protocol for an open-label, two-cohort, phase II trial

Publication history

  • Received November 5, 2019
  • Revised August 18, 2020
  • Accepted September 21, 2020
  • First published October 15, 2020.
Online issue publication 
October 15, 2020
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.